Fortive

FTV · NYSE

$58.36+$0.88 (+1.53%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $57.48

FTV analyst rating

HoldConsensus of 13 analysts over the last 12 months. 15% rate it a buy.

Strong buy0
Buy2
Hold8
Underperform3
Sell0

12-month price target · 17 analysts

Average $64.91 (+11.2% upside)

Low: $51.51
Now: $58.36
High: $73.50

Upgrades and downgrades

The latest rating actions, newest first

FTV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Oct 14, 2026	Maintains	Sector Perform	$63.00 → $59.00	43%
JP Morgan	Oct 9, 2026	Maintains	Underweight	$64.00 → $56.00	64%
Truist Securities	Oct 5, 2026	Maintains	Hold	$68.00 → $63.00	59%
Evercore ISI Group	Sep 28, 2026	Initiates	In-Line	$60.00	35%
Argus Research	Aug 19, 2026	Maintains	Buy	$68.00	65%
Truist Securities	Jul 30, 2026	Maintains	Hold	$67.00 → $68.00	59%
Truist Securities	Jul 2, 2026	Maintains	Hold	$61.00 → $67.00	59%
Morgan Stanley	Jun 3, 2026	Maintains	Equal-Weight	$58.00 → $59.00	68%
JP Morgan	May 12, 2026	Maintains	Underweight	$63.00 → $64.00	64%
Argus Research	May 11, 2026	Upgrade	Hold → Buy	$68.00	65%

The case for and against

Updated Oct 21, 2026

Bull case

Fortive is attractive because its first-quarter adjusted EPS rose 25.4% year over year to $0.70, while sales increased 7.7% to $1.069B and core growth of 5.3% came from both price and volume across regions and segments. Operating performance also strengthened, with adjusted EBITDA up 13.2% to $314M and margin expanding 140 bps to 29.3%, supported by operating leverage, structural cost savings, and favorable FX despite tariff pressure. Its outlook is reinforced by broad-based North America strength, resilient recurring revenue in Fluke and healthcare consumables/software, healthy backlog and book-to-bill above 1.0, and reaffirmed 2026 EPS guidance of $2.90-$3.00 alongside continued buybacks and bolt-on M&A.

Bear case

Fortive is viewed negatively because tariffs are still pressuring gross margins and are expected to remain a headwind partway through 3Q before countermeasures lap in 4Q, while broader macro risks, supply-chain issues, and currency or material-cost inflation could keep results below forecast. The company’s upside depends heavily on sustained organic growth, rising recurring/software revenue, and disciplined bolt-on M&A, yet any disappointment there could trigger multiple compression as investors monitor progress against relatively near-term 2026-2027 targets. Even after a positive 2.2% price realization and a 4c/5% 1Q26 operating beat, Fortive’s shares still trade at 18.4x 2027E P/E, a 19% discount to peers, implying the market is already skeptical about durability and execution.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.